Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis is a promising investment opportunity with a strong pipeline and potential catalysts in the upcoming months, including 2-year safety data for their lead drug envudeucitinib in Phase II PsO trials and an NDA submission for envudeucitinib in PsO in 4Q26. The company also has a diversified pipeline, including A-005, a brain-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, and a new clinical candidate in Phase I trials. The company's valuation is fair, with a 12-month price objective of $25 based on a discounted cash flow model, but risks such as potential delays and competition in the market should be considered.

Bears say

Alumis is a clinical-stage biopharmaceutical company with a focus on developing two TYK2 inhibitors for the treatment of Psoriasis andSLE. While the company's Phase IIb study missed both primary and secondary endpoints in the overall population, the higher-than-expected placebo response in the IFNGS-low subgroup and the lower proportion of SLE patients with severe disease could have influenced the results. The company also faces competition in the market from both in-class therapies and other therapeutic modalities, and may need additional financing before reaching profitability.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Strong Buy consensus rating as of Sep 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.